Translatum Medicus Inc is a preclinical drug development company focused on macrophage modulation to treat blinding eye disease, with a patented lead drug candidate, TMi-018 for the treatment of dry Age-Related Macular Degeneration (AMD). Translatum is based in the Johnson & Johnson Innovation Incubator JLABS@Toronto, and has been increasingly gaining traction as one of the most innovative early stage ophthalmic biotech companies.